The pharmaceutical industry is increasingly driven by GLP-1 obesity therapies, reshaping clinical practice, formulary strategies, biologic innovation, and precision medicine across multiple specialties.

New research shows tuberculosis infectiousness varies widely, challenging traditional assessment methods and supporting updated isolation guidelines, improved risk evaluation, and more targeted infection-control strategies.

Hospital discharge antibiotic prescribing is becoming a stewardship priority, aiming to reduce unnecessary treatments, antimicrobial resistance, avoidable side effects, and preventable hospital readmissions.

Colistin-meropenem combination therapy may improve treatment of severe carbapenem-resistant infections, prompting closer monitoring, rapid diagnostics, and updated antibiotic stewardship strategies in critical care settings.

GLP-1 medications for diabetes and obesity may also support mental health, prompting integrated monitoring of mood, anxiety, and overall wellbeing during treatment and follow-up.

Long-standing atrial fibrillation can cause tricuspid regurgitation, highlighting the need for earlier detection, coordinated care, and emerging catheter-based treatment strategies for patients.

Setidegrasib, a novel KRAS G12D-targeted protein degrader, showed promising tumor responses in pancreatic and lung cancers, advancing precision oncology and personalized cancer treatment strategies.

A recent study found 5% of Americans carry inherited cancer-risk variants, highlighting genetic testing’s growing role in personalized prevention, surveillance, and precision oncology care.

Advances in molecular diagnostics are improving primary myelofibrosis classification, enabling more precise diagnoses, personalized treatments, and targeted therapies based on patients’ genetic profiles.

Policy changes and healthcare inequities are limiting women’s access to reproductive and maternal care, disproportionately affecting low-income, marginalized, and gender-diverse populations nationwide.